• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL

    4/28/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CORT alert in real time by email

    Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quarter financial results and provide a corporate update on May 5, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

    Conference Call Information

    Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller.

    Additionally, a listen-only webcast will be available by clicking here.

    A replay of the call will be available on the Investors / Events tab of Corcept.com.

    About Corcept Therapeutics

    For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders, leading to the discovery of more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Corcept.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250428138745/en/

    Investor inquiries:

    [email protected]

    Media inquiries:

    [email protected]

    www.corcept.com

    Get the next $CORT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CORT

    DatePrice TargetRatingAnalyst
    11/6/2023$29.00 → $38.00Hold → Buy
    Truist
    4/11/2023$25.00Market Perform
    SVB Securities
    4/4/2023$27.00Overweight
    Piper Sandler
    2/15/2023$35.00 → $22.00Buy → Hold
    Jefferies
    8/1/2022$30.00Buy → Hold
    Truist
    7/27/2022$21.00 → $35.00Hold → Buy
    Jefferies
    6/27/2022$30.00 → $34.00Buy
    Canaccord Genuity
    2/2/2022$30.00Buy
    Canaccord Genuity
    More analyst ratings

    $CORT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

      Revenue of $157.2 million, compared to $146.8 million in first quarter 2024 Reiterated 2025 revenue guidance of $900 – $950 million Net income per common share (diluted) of $0.17, compared to $0.25 in first quarter 2024 Cash and investments of $570.8 million as of March 31, 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat serious endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2025. Financial Results "In the first quarter, we had another record number of prescrip

      5/5/25 4:05:00 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL

      Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quarter financial results and provide a corporate update on May 5, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therapeutics For

      4/28/25 4:05:00 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

      Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data will be presented in a late-breaking oral presentation on Monday, June 2, 2025. Title: ROSELLA: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Patients w

      4/23/25 11:30:00 AM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CORT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

      SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

      3/27/24 2:32:52 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

      SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

      2/14/24 4:23:00 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

      SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

      2/13/24 5:02:29 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CORT
    Financials

    Live finance-specific insights

    See more

    $CORT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CORT
    SEC Filings

    See more

    $CORT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

      Revenue of $157.2 million, compared to $146.8 million in first quarter 2024 Reiterated 2025 revenue guidance of $900 – $950 million Net income per common share (diluted) of $0.17, compared to $0.25 in first quarter 2024 Cash and investments of $570.8 million as of March 31, 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat serious endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2025. Financial Results "In the first quarter, we had another record number of prescrip

      5/5/25 4:05:00 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL

      Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quarter financial results and provide a corporate update on May 5, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therapeutics For

      4/28/25 4:05:00 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update

      2024 revenue of $675.0 million, a 40 percent increase over 2023 2025 revenue guidance of $900 – $950 million 2024 net income of $141.2 million, a 33 percent increase over 2023 Cash and investments of $603.2 million as of December 31, 2024 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2024. Financial Results "Once again, we had a record number of new Korlym® prescribers and a record number of p

      2/26/25 4:05:00 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Guyer William exercised 7,060 shares at a strike of $21.65 and sold $524,653 worth of shares (7,060 units at $74.31) (SEC Form 4)

      4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

      5/8/25 8:20:53 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Maduck Sean exercised 39,410 shares at a strike of $5.05 and sold $2,842,769 worth of shares (39,410 units at $72.13) (SEC Form 4)

      4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

      5/5/25 8:33:21 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Belanoff Joseph K sold $2,915,922 worth of shares (40,000 units at $72.90) (SEC Form 4)

      4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

      5/5/25 8:28:36 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Corcept Therapeutics Incorporated

      10-Q - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

      5/5/25 4:09:36 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corcept Therapeutics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

      5/5/25 4:07:56 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Corcept Therapeutics Incorporated

      DEF 14A - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

      4/25/25 4:11:17 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corcept Therapeutics upgraded by Truist with a new price target

      Truist upgraded Corcept Therapeutics from Hold to Buy and set a new price target of $38.00 from $29.00 previously

      11/6/23 7:25:25 AM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Securities initiated coverage on Corcept Therapeutics with a new price target

      SVB Securities initiated coverage of Corcept Therapeutics with a rating of Market Perform and set a new price target of $25.00

      4/11/23 7:25:02 AM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Corcept Therapeutics with a new price target

      Piper Sandler initiated coverage of Corcept Therapeutics with a rating of Overweight and set a new price target of $27.00

      4/4/23 7:17:46 AM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CORT
    Leadership Updates

    Live Leadership Updates

    See more
    • Corcept Appoints Roberto Vieira as President, Oncology

      MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the appointment of Roberto Vieira as President, Oncology. He will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Mr. Vieira joins Corcept from Mirati Therapeutics, Inc., where he served as Senior Vice President of U.S. Commercial until earlier this month. At Mirati, Mr. Vieira built the U.S. commercial o

      1/29/24 8:00:00 AM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corcept Appoints Monica Tellado as President, Emerging Markets

      MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by modulating the effects of the hormone cortisol, today announced the appointment of Monica Tellado as President, Emerging Markets. She will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Ms. Tellado's prior role was at Heartflow, where she served as Chief Financial Officer. Before joining Heartflow, Ms. Tellado spent 19 years in ascending leadership roles at Gilead Science

      11/1/23 8:00:00 AM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corcept Therapeutics Announces Appointment of Three Senior Leaders

      MENLO PARK, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol, today announced the appointment of three individuals to Commercial and Development leadership roles. Daniel Einhorn, MD, FACP, FACE, has joined Corcept as Vice President, Endocrine Strategy; Amiel Balagtas has joined as Vice President, Development Operations; and Lyndah Dreiling, MD, has joined as Vice President, Global Oncology Development. Dr. Einhorn will report to Sean Maduck, Presid

      4/7/22 4:05:00 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care